首页> 外国专利> Bacterial capsular polysaccharide for use as a vaccine or for protein binding in conjugate vaccines

Bacterial capsular polysaccharide for use as a vaccine or for protein binding in conjugate vaccines

机译:用作疫苗或结合疫苗中蛋白质结合的细菌荚膜多糖

摘要

An immunogenic composition comprising a purified group B streptococcal capsular polysaccharide, in which the purified group B streptococcal polysaccharide is produced by a process comprising - providing for isolated extraction bacterial cells, concentrated bacterial supernatants from homogenized bacterial cells or of conditioned medium or sedimented cells comprising a group B streptococcal capsular polysaccharide; - extracting the capsular polysaccharide from the cellular components, in which the cellular components include nucleic acids and proteins by contacting isolated bacterial cells, concentrated bacterial supernatants from homogenized bacterial cells or the conditioned medium or sedimented cells with a basic reagent selected from the NaOH, KOH, LiOH, NaH, NaOMe or KOtBu bases, in which the bases are used in a range of 0.5 N to 5.0 N and in which the DNA and RNA are degraded bacterial; - separating by means of hydrophobic interaction chromatography (CIH) the capsular polysaccharide extracted from the impurities resulting from the cellular components comprising proteins and nucleic acids; and - recovering the purified capsular polysaccharide; in which the group B streptococcal capsular polysaccharide is selected from the group consisting of PC of type Ia, PC of type Ib, PC of type II, PC of type III and PC of type V and in which: the PC of type Ia, after said separation stage, has Kav in the range of 0.010 - 0.005 Mw in the range of 318-311 (kg / mol) Mw / Mn in the range of 1.35 - 1.31; the type Ib PC, after said separation stage, has Kav in the range of 0.191-0.150 Mw in the range of 218-170 (kg / mol) Mw / Mn in the range of 1.61-1.20; the type II PC, after said separation stage, has Kav in the range of 0.152-0.115 Mw in the range of 289-246 (kg / mol) Mw / Mn in the range of 1.46; the type III PC, after said separation stage, has Kav in the range of 0.343-0.268 Mw in the range of 108-104 (kg / mol) Mw / Mn in the range of 1.24-1.22; the type V PC, after said separation stage, has Kav in the range of 0.257-0.156 Mw in the range of 179-92 (kg / mol) Mw / Mn in the range of 1.28-1.15. **Formula**
机译:包含纯化的B组链球菌荚膜多糖的免疫原性组合物,其中纯化的B组链球菌多糖是通过以下方法制备的:-提供分离的提取细菌细胞,匀浆细菌细胞的浓缩细菌上清液或条件培养基或沉淀细胞,包括B组链球菌荚膜多糖; -从细胞成分中提取荚膜多糖,其中细胞成分包括核酸和蛋白质,方法是使分离的细菌细胞,来自均质细菌细胞或条件培养基或沉淀细胞的浓缩细菌上清液与选自NaOH,KOH的碱性试剂接触LiOH,NaH,NaOMe或KOtBu碱,其中碱的使用范围为0.5 N至5.0 N,并且DNA和RNA是降解的细菌; -通过疏水相互作用色谱法(CIH)分离从杂质中提取的荚膜多糖,所述杂质是由包含蛋白质和核酸的细胞组分产生的; -回收纯化的荚膜多糖;其中B组链球菌荚膜多糖选自Ia型PC,Ib型PC,II型PC,III型PC和V型PC,其中:Ia型PC所述分离阶段的Kav在0.010-0.005Mw的范围内,在318-311(kg / mol)Mw / Mn的范围内,在1.35-1.31的范围内;在所述分离阶段之后,Ib型PC的Kav在0.191-0.150Mw的范围内,在218-170(kg / mol)Mw / Mn的范围内在1.61-1.20;在所述分离阶段之后,II型PC的Kav在0.152-0.115Mw的范围内,在289-246(kg / mol)Mw / Mn的范围内在1.46;在所述分离阶段之后,III型PC的Kav在0.343-0.268Mw的范围内,在108-104(kg / mol)Mw / Mn的范围内在1.24-1.22;在所述分离阶段之后,V型PC具有的Kav值在0.257-0.156Mw的范围内,在179-92(kg / mol)Mw / Mn的范围内在1.28-1.15的范围内。 **式**

著录项

  • 公开/公告号ES2611464T3

    专利类型

  • 公开/公告日2017-05-09

    原文格式PDF

  • 申请/专利权人 PFIZER IRELAND PHARMACEUTICALS;

    申请/专利号ES20100005184T

  • 发明设计人 MICHON FRANCIS;BLAKE MILAN;

    申请日1998-12-23

  • 分类号C08B37;C12P19/04;C12P19/26;C12R1/01;C12R1/46;

  • 国家 ES

  • 入库时间 2022-08-21 13:35:21

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号